ClinicalTrials.gg
CompletedNCT05618808Updated Aug 29, 2025Results posted

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

A Phase 2 interventional study of REGN9933 and Enoxaparin in Venous Thromboembolism, sponsored by Regeneron Pharmaceuticals. Completed at 16 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Venous Thromboembolism with a site in Latvia — 2 open to participants now, 2 under way, 1 of them phase 3. Venous Thromboembolism · Latvia.

Enrollment
16th of 19
373 · median 1,146
Started
2023
the only one that year
Phase 2
8 of 22
none open now
Registered
20th of 22
by date
Lead sponsor
3 of 22
Regeneron Pharmaceuticals

Among the 22 studies in Venous Thromboembolism with a site in Latvia, this one is the 16th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2023, is one of 8 in phase 2, and was the 20th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

2 of the 22 studies in Venous Thromboembolism with a site in Latvia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Latvia have not opened yet or have stopped. Only those recruiting at a site in Latvia →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Venous Thromboembolism with a site in Latvia, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin

The secondary objectives of the study are:

  • To evaluate the bleeding risk (ie, major and clinically relevant non-major [CRNM] bleeding) of REGN9933 after unilateral TKA through time of venography, compared to enoxaparin
  • To assess overall safety and tolerability of REGN9933 in participants undergoing TKA
  • To evaluate the efficacy of REGN9933 in prevention of clinically relevant VTE, compared to enoxaparin
  • To evaluate the efficacy of REGN9933 in prevention of deep venous thrombosis (DVT) detected by venography, compared to enoxaparin
  • To evaluate the pharmacokinetics (PK) of REGN9933 after single intravenous (IV) administration
  • To assess pharmacodynamic (PD) effects of REGN9933 on intrinsic and extrinsic coagulation pathways
  • To assess immunogenicity following a single dose of REGN9933 over time
  • To compare the efficacy of enoxaparin and apixaban in prevention of VTE after unilateral TKA
03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Anti-factor XI (FXI) monoclonal antibody
  • Deep Vein Thrombosis
  • Unilateral total knee arthroplasty (TKA),
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Undergoing elective unilateral TKA
  2. Has a body weight ≤130 kg at screening visit
  3. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and (ECG) performed at screening and/or prior to administration of initial dose of study drug
  4. Is in good health based on laboratory safety testing obtained during the screening period as described in the protocol

Key Exclusion Criteria:

  1. History of bleeding in the past 6 months requiring hospitalization or transfusion; history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, and traumatic spinal or epidural anesthesia; history of bleeding diathesis.
  2. History of thromboembolic disease or thrombophilia
  3. History of major surgery, including brain, spinal, or ocular, within approximately the past 6 months.
  4. History of major trauma within approximately the past 6 months.
  5. Hospitalized (>24 hours) for any reason within 30 days of the screening visit
  6. Using the Modification of Diet in Renal Disease equation, has an estimated as described in the protocol

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    REGN9933

    REGN9933 will be administered by intravenous (IV) infusion

    Drug: REGN9933

  • Active comparator
    Enoxaparin

    Enoxaparin will be administered by subcutaneous (SC) administration

    Drug: Enoxaparin

  • Active comparator
    Apixaban

    Apixaban will be administered orally twice a day

    Drug: Apixiban

Interventions

  • Participants will receive a single dose of REGN9933 by IV infusion

  • Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)

    Also known as: Lovenox

  • Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)

    Also known as: Eliquis

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)

    Composite endpoint that includes: asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out

    Time frame: Through Day 12

Secondary outcomes

  1. Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding

    International Society on Thrombosis and Hemostasis (ISTH) criteria for Major Bleeding and CRNM Bleeding as described in the protocol

    Time frame: Through Day 12

  2. Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)

    A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Day 75

  3. Percentage of Participants With Major VTE (REGN9933 vs Enoxaparin)

    Major VTE is a composite endpoint that includes: proximal DVT; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal PE including unexplained death for which PE cannot be ruled out

    Time frame: Through Day 12

  4. Percentage of Participants With DVT (REGN9933 vs Enoxaparin)

    DVT measured by venography of the operated leg

    Time frame: Through Day 12

  5. Total REGN9933 Concentrations in Serum

    The concentrations of REGN9933 over time were summarized by descriptive statistics by study arm for the overall population

    Time frame: Days 0.0625 (post-dose), 4, 9, 29, and 74

  6. Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

    aPTT was used to measure the anticipated anticoagulant effect of REGN9933. Fold change is based on the follow-up value/baseline value within an arm.

    Time frame: Days 1, 5, 10, 30, and 75

  7. Fold Change From Baseline in Prothrombin Time (PT)

    PT is a measure of extrinsic and/or common pathway function. Fold change is based on the follow-up value/baseline value within an arm.

    Time frame: Days 1, 5, 10, 30, and 75

  8. Number of Participants With Anti-REGN9933 Antibodies by Status

    Immunogenicity characterized by anti-drug antibody (ADA) status

    Time frame: Through Day 75

  9. Number of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN13335 Antibodies by Maximum Titer Level

    Immunogenicity characterized per drug molecule by ADA status

    Time frame: Through Day 75

  10. Percentage of Participants With Confirmed, Adjudicated VTE (Enoxaparin vs Apixaban)

    Asymptomatic deep DVT detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.

    Time frame: Through Day 12

07

Results

Posted Jul 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneREGN9933EnoxaparinApixaban
Started123125125
Completed120124122
Not completed313
Withdrew: Withdrawal by subject313

Outcome measures

PrimaryPercentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)

Composite endpoint that includes: asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out

Time frame:
Through Day 12
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)
percentage of participantsREGN9933Enoxaparin
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)17.222.2
Statistical analysis
  • REGN9933 vs Enoxaparin · Posterior odds ratio: 0.78 · 90% CI 0.47 to 1.32REGN9933 vs Enoxaparin
SecondaryNumber of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding

International Society on Thrombosis and Hemostasis (ISTH) criteria for Major Bleeding and CRNM Bleeding as described in the protocol

Time frame:
Through Day 12
Reported as:
Count of participants · Participants
Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding
ParticipantsREGN9933EnoxaparinApixaban
Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding000
SecondaryPercentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)

A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to Day 75
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
percentage of participantsREGN9933EnoxaparinApixaban
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)22.020.824.8
SecondaryPercentage of Participants With Major VTE (REGN9933 vs Enoxaparin)

Major VTE is a composite endpoint that includes: proximal DVT; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal PE including unexplained death for which PE cannot be ruled out

Time frame:
Through Day 12
Reported as:
Number · percentage of participants
Percentage of Participants With Major VTE (REGN9933 vs Enoxaparin)
percentage of participantsREGN9933Enoxaparin
Percentage of Participants With Major VTE (REGN9933 vs Enoxaparin)02.6
Statistical analysis
  • REGN9933 vs Enoxaparin · Posterior odds ratio: 0.44 · 90% CI 0.16 to 1.61REGN9933 vs Enoxaparin
SecondaryPercentage of Participants With DVT (REGN9933 vs Enoxaparin)

DVT measured by venography of the operated leg

Time frame:
Through Day 12
Reported as:
Number · percentage of participants
Percentage of Participants With DVT (REGN9933 vs Enoxaparin)
percentage of participantsREGN9933Enoxaparin
Percentage of Participants With DVT (REGN9933 vs Enoxaparin)17.222.2
Statistical analysis
  • REGN9933 vs Enoxaparin · Posterior odds ratio: 0.79 · 90% CI 0.47 to 1.32REGN9933 vs Enoxaparin
SecondaryTotal REGN9933 Concentrations in Serum

The concentrations of REGN9933 over time were summarized by descriptive statistics by study arm for the overall population

Time frame:
Days 0.0625 (post-dose), 4, 9, 29, and 74
Reported as:
Mean · milligrams/Liter (mg/L)
Total REGN9933 Concentrations in Serum
milligrams/Liter (mg/L)REGN9933
Day 0.0625 (post-dose)65.6 ± 18.2
Day 434.9 ± 9.65
Day 923.7 ± 7.15
Day 295.51 ± 3.47
Day 740.140 ± 0.107
SecondaryFold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

aPTT was used to measure the anticipated anticoagulant effect of REGN9933. Fold change is based on the follow-up value/baseline value within an arm.

Time frame:
Days 1, 5, 10, 30, and 75
Reported as:
Mean · Fold Change
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)
Fold ChangeREGN9933EnoxaparinApixaban
Day 11.84 ± 0.245——
Day 52.26 ± 0.3091.11 ± 0.1431.16 ± 0.163
Day 102.17 ± 0.4431.04 ± 0.1141.10 ± 0.117
Day 301.56 ± 0.3851.01 ± 0.1491.04 ± 0.129
Day 751.01 ± 0.1321.01 ± 0.1191.03 ± 0.120
SecondaryFold Change From Baseline in Prothrombin Time (PT)

PT is a measure of extrinsic and/or common pathway function. Fold change is based on the follow-up value/baseline value within an arm.

Time frame:
Days 1, 5, 10, 30, and 75
Reported as:
Mean · Fold Change
Fold Change From Baseline in Prothrombin Time (PT)
Fold ChangeREGN9933EnoxaparinApixaban
Day 11.01 ± 0.075——
Day 50.96 ± 0.0860.94 ± 0.0641.02 ± 0.091
Day 100.95 ± 0.1080.94 ± 0.0731.00 ± 0.089
Day 300.99 ± 0.2200.97 ± 0.1220.99 ± 0.183
Day 750.94 ± 0.1450.93 ± 0.0920.94 ± 0.073
SecondaryNumber of Participants With Anti-REGN9933 Antibodies by Status

Immunogenicity characterized by anti-drug antibody (ADA) status

Time frame:
Through Day 75
Reported as:
Count of participants · Participants
Number of Participants With Anti-REGN9933 Antibodies by Status
ParticipantsREGN9933
Negative118
Pre-existing Immunoreactivity1
Treatment-emergent (TE) Response0
Treatment-boosted (TB) Response0
SecondaryNumber of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN13335 Antibodies by Maximum Titer Level

Immunogenicity characterized per drug molecule by ADA status

Time frame:
Through Day 75
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN13335 Antibodies by Maximum Titer Level
ParticipantsREGN9933
Low (<1,000)0
Moderate (1,000 to 10,000)0
High (>10,000)0
SecondaryPercentage of Participants With Confirmed, Adjudicated VTE (Enoxaparin vs Apixaban)

Asymptomatic deep DVT detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.

Time frame:
Through Day 12
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed, Adjudicated VTE (Enoxaparin vs Apixaban)
percentage of participantsEnoxaparinApixaban
Percentage of Participants With Confirmed, Adjudicated VTE (Enoxaparin vs Apixaban)22.212.4
Statistical analysis
  • Enoxaparin vs Apixaban · Posterior odds ratio: 0.54 · 90% CI 0.32 to 0.95Enoxaparin vs Apixaban

Adverse events

Collected over From date of signing informed consent form (ICF) up to end of study (approximately 105 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REGN99330/123 (0%)4/123 (3.3%)9/123 (7.3%)
Enoxaparin0/125 (0%)1/125 (0.8%)11/125 (8.8%)
Apixaban0/125 (0%)2/125 (1.6%)16/125 (12.8%)
Most frequent serious events
Most frequent serious events
EventREGN9933EnoxaparinApixaban
Atrial fibrillationCardiac disorders1/1230/1250/125
CholecystitisHepatobiliary disorders1/1230/1250/125
Device related infectionInfections and infestations1/1230/1250/125
Urinary retentionRenal and urinary disorders1/1230/1250/125
Angina pectorisCardiac disorders0/1230/1251/125
Soft tissue infectionInfections and infestations0/1231/1250/125
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1230/1251/125
Most frequent other events
Most frequent other events
EventREGN9933EnoxaparinApixaban
Anaemia postoperativeInjury, poisoning and procedural complications9/12311/12516/125

Baseline characteristics

Age, Continuous
Age, Continuous(Years)REGN9933EnoxaparinApixabanTotal
Mean66.5 ± 7.7366.6 ± 7.6166.5 ± 7.6966.5 ± 7.66
Sex: Female, Male
Sex: Female, Male(Participants)REGN9933EnoxaparinApixabanTotal
Female9510489288
Male28213685
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REGN9933EnoxaparinApixabanTotal
Hispanic or Latino3249
Not Hispanic or Latino120121121362
Unknown or Not Reported0202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REGN9933EnoxaparinApixabanTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White123125125373
More than one race0000
Unknown or Not Reported0000
08

Study locations

16 sites
  • Ziekenhuis Oost-Limburg- Campus Sint-Jan
    Genk, Limburg 3600, Belgium
  • MBAL Heart and Brain Hospital
    Pleven, 5800, Bulgaria
  • Durham Bone and Joint Specialists
    Ajax, Ontario L1S 7K7, Canada
  • MAV Korhaz es Rendelointezet Szolnok
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Department of Orthopedics, Somogy County Mór Kaposi Teaching Hospital
    Kaposvár, 7400, Hungary
  • Liepaja Regional Hospital
    Liepāja, LV3414, Latvia
  • Vidzemes Hospital
    Riga, LV-1002, Latvia
  • Riga's 2nd Hospital
    Riga, LV-1004, Latvia
  • Hospital of Traumatology and Orthopaedics
    Riga, LV1005, Latvia
  • Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinik
    Kaunas, Kaunas County LT-50009, Lithuania
  • Klaipeda University Hospital
    Klaipėda, Klaipėda County LT-92288, Lithuania
  • Lietuvos Sveikatos Mokslu Universiteto Kauno Ligoninė
    Kaunas, LT-44320, Lithuania
  • Specjalistyczny Szpital im. E. Szczeklika w Tarnowie
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • SP ZOZ Centralny Szpital Kliniczny UM w Lodzi
    Lodz, 90-153, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
    Lublin, 20-954, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Radzyniu Podlaskim
    Radzyń Podlaski, 21-300, Poland
09

References and documents

Publications

  • Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29;406(10519):2551-2563. doi: 10.1016/S0140-6736(25)02097-5. Epub 2025 Nov 8. PubMed 41218619 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in May 2024, 12 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 16, 2022
StartActual
May 24, 2023
Primary completionActual
May 27, 2024
CompletionActual
May 27, 2024
Results first posted
Jul 16, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05618808
Responsible party
Sponsor
First posted
Nov 16, 2022
Start date
May 24, 2023
Primary completion
May 27, 2024
Completion
May 27, 2024
Results posted
Jul 16, 2025
Last update
Aug 29, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrecibart

Start the discussion